Showing 61-70 of 454 results
This exclusive agreement broadens Helsinn’s existing partnerships for anamorelin in the area of cancer supportive care across multiple global territories
The exclusive agreement builds on our existing partnerships in the area of cancer supportive care across multiple global territories
The exclusive agreement builds on our existing partnerships in the area of cancer supportive care across multiple global territories
Elsiglutide is a GLP-2 receptor agonist with potential as a first-ever therapy to help cancer patients avoid a serious and life-threatening condition •The first patients have been treated in this Phase IIB dose-finding trial and study results are expected in H1 2016
Decision of the National Comprehensive Cancer Network (NCCN) to include AKYNZEO® in the 2015 NCCN Antiemesis Guidelines as a recommended option for patients receiving both highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC).
TGA Approves AKYNZEO® (netupitant/palonosetron) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) First New Fixed Combination Targeting Two Critical Pathways Involved in CINV
Helsinn, a Swiss Group focused on building quality cancer care, announced today that three abstracts highlighting new study results will be presented at the 51th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago from 29 May to 2 June, 2015.
The European approval of ALOXI® for paediatric use follows the FDA approval in May 2014 of ALOXI® for paediatric use in the US
Helsinn, the Swiss Group focused on building quality cancer care, announces today that its recently launched Helsinn Integrative Care division is meeting the cancer community at booth 6033 at the American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, Chicago, Illinois.
Helsinn, the Swiss Group focused on building quality cancer care, announces today that on 27th May 2015, the European Commission (EC) approved Akynzeo® (netupitant-palonosetron) for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin based cancer chemotherapy and moderately emetogenic cancer chemotherapy in the European Union.